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The endothelial nitric oxide synthase gene (NOS3) has been implicated in the development of hypertension, although the speciﬁc
role of variants and haplotypes has not been clariﬁed. In this study, the association of three polymorphisms (promoter T786C,
intronic 4a/b, and nonsynonymous G894T) was tested in a case-control sample of 230 patients with essential hypertension and
306 healthy controls. Haplotype analysis was also performed. The mutant allele a∗ of the 4a/b polymorphism showed a protective
eﬀect against hypertension under a dominant model (odds ratio = 0.64, 95% conﬁdence interval (0.44–0.93)), although this eﬀect
was not signiﬁcant after the adjustment for covariates (P = 0.06). The estimated frequency of the haplotype composed of the
T786
∗,4 a ∗, and G894
∗ alleles was signiﬁcantly higher in controls (5.5%) compared to cases (2%). These results indicate that
although individual NOS3 polymorphisms are not associated with hypertension, a rare haplotype of the gene might be protective
against the development of hypertension.
1.Introduction
Hypertension is a multifactorial disorder resulting from
complex interactions between genetic and environmental
contributions. An increase in vascular resistance and impair-
mentofendothelial-dependentvasodilatationareinvolvedin
the pathogenesis of the disease. Nitric oxide (NO) synthesis
by the vascular endothelium is important for the regulation
of vasodilator tone and control of blood pressure in humans
[1, 2]. Given the pivotal role of NO in vascular homeostasis,
the endothelial nitric oxide synthase gene (NOS3)h a s
emerged as a logical candidate gene in the investigation of
hypertension genetics [3].
VariantsoftheNOS3genelocatedinthe7q35-q36region
have been investigated for association with hypertension
and other cardiovascular disorders [3]. Among them, three
polymorphisms have been widely examined for clinical
relevance, based on their potential functional eﬀects and
their relatively high minor allele frequency in various ethnic
groups [3, 4]: (i) a G894T substitution in exon 7 resulting
in a Glu to Asp substitution at codon 298 (rs1799983),
(ii) an insertion-deletion in intron 4 (4a/b) consisting
of two alleles (the a∗-deletion which has four tandem
27-bp repeats and the b∗-insertion having ﬁve repeats),
and (iii) a T786C substitution in the promoter region
(rs2070744). In a survey of all published association studies
on the relation between the NOS3 gene polymorphisms and
the risk of hypertension, a meta-analysis and subsequent
sensitivity analyses supported an association only for the
4a/b polymorphism and hypertension [5]. Most of the
studies in the ﬁeld had investigated the eﬀects of individual
polymorphisms and reported marginal or even controversial
associations. However, accumulating evidence shows that
signiﬁcant interactions between individual NOS3 polymor-
phisms have a major inﬂuence on NO formation [6, 7], and
consequently an analysis of haplotypes (and not individual
NOS3 polymorphisms) is expected to be a more powerful
approach for detecting genetic susceptibility to hypertension
[8, 9].2 International Journal of Hypertension
In order to replicate [10] the association described
in the above meta-analysis [5] and explore the eﬀects of
NOS3 haplotypes on the risk of developing hypertension,
we performed a case-control study to test for associa-
tion between NOS3 polymorphisms (or haplotypes) and
hypertension. We focused on the three previously studied
polymorphisms (T786C, 4a/b, and G894T) because of their
potential functional implications, their high minor allele
frequency, and the extensive publication record on them that
would allow for meaningful comparisons [3, 4]. The study
presented here was conducted in a case-control sample from
a homogeneous population of Caucasian origin (Greeks).
2.MaterialsandMethods
2.1. Study Population. All consecutive hypertensive patients
presentinginourrecruitmentcenters(primarycarepractices
and outpatient clinics) were systematically evaluated for
fulﬁllment of the following inclusion criteria: (1) patient
age more than 20 years, (2) age-at-onset of hypertension
before 60 years of age (in order to obtain a phenotype
with enriched genetic component) [11], (3) established
hypertension deﬁned either as long-term treatment of the
disease or in those previously untreated with systolic blood
pressure (SBP) more than 140mmHg or diastolic blood
pressure (DBP) more than 90mmHg, (4) documented
absenceofsecondaryformsofhypertensionafterclinicaland
laboratoryworkup(suchasrenal,renovascularorendocrine
disease) and (5) absence of diabetes mellitus. A total of
230 nondiabetic patients with essential hypertension were
ﬁnally recruited. Each patient’s medical history was obtained
using a standardized questionnaire regarding the lifestyle,
smoking (current or ex-smokers), alcohol or drug intake.
Medical history of hypertension, cardiovascular disease,
hyperlipidemia, and current medications was recorded. A
complete physical examination was performed including
measurementofsupineSBPandDBP(usingmercury column
sphygmomanometers), electrocardiogram recording, and
measurement of somatometric parameters (height, weight,
body mass index (BMI)). Spouses and friends of cases were
interviewed to assess their appropriateness for inclusion as a
healthy control group. A group of 306 normotensive, healthy
control subjects was also recruited according to the following
criteria: (1) subject age more than 20 years, (2) absence of
hypertension or antihypertensive treatment in the medical
history, (3) SBP/DBP less than 140/90mmHg, respectively,
(4) absence of chronic illness (renal, cardiovascular, mental,
hepatic, endocrine disorders or cancer) or concomitant
chronic medication, and (5) unrelated by blood to cases.
A blood sample for biochemical measurements and DNA
extraction was taken from each participant. All participants
provided written informed consent.
2.2. Laboratory Assays. Genomic DNA was extracted from
whole blood using the QIAamp DNA blood kit (QIAGEN,
Valencia, CA, USA) following the manufacturer’s instruc-
tion. Genotyping of each polymorphism was performed
by ampliﬁcation from 50 to 100ng of genomic DNA. The
Table 1: Clinical characteristics of cases and controls.
Cases (n = 230) Controls (n = 306) P-value
Age (years) 63.9 (9.4) 40.8 (18.3) <.05
Males, n (%) 125 (54.4) 68 (22.2) <.05
BMI 28.7 (4.1) 27.5 (4.4) <.05
Smokers, n (%) 84 (36.5) 80 (29.9) .08
SBP (mmHg) 145.3 (15.7) 124.4 (12.3) <.05
DBP (mmHg) 85.1 (10.2) 68.8 (9.7) <.05
PP (mmHg) 59.3 (17.2) 57.1 (14.1) .19
CAD, n (%) 65 (28.3) — N/A
Creatinine
(mg/dL)
1.09 (0.8) 0.92 (0.9) <.05
Urea (mg/dL) 40.8 (8.6) 36.5 (6.6) <.05
Potassium
(mmol/L)
4.3 (0.5) 4.4 (0.3) .26
Sodium
(mmol/L)
138.4 (3.1) 140.0 (4.5) .38
Total
Cholesterol
(mg/dL)
190.88 (48.4) — N/A
LDL Cholesterol
(mg/dL)
113.7 (39.5) — N/A
HDL
Cholesterol
(mg/dL)
46.9 (17.8) — N/A
Triglycerides
(mg/dL)
132.4 (64.5) — N/A
Drug treatment
(%)
89.6 — N/A
ACE-inhibitors
(%)
45.2 — N/A
ARBs (%) 29.0 — N/A
Beta-blockers
(%)
50.3 — N/A
CCBs (%) 36.8 — N/A
Diuretics (%) 50.9 — N/A
Nitrates (%) 13.5 — N/A
Statins (%) 39.7 — N/A
Values are mean (standard deviation), unless otherwise speciﬁed. Abbrevia-
tions:BMI=bodymassindex,SBP=systolicbloodpressure,DBP=diastolic
blood pressure, PP = pulse pressure, CAD = coronary artery disease, LDL =
low-densitylipoprotein,HDL=highdensitylipoprotein,ACE=angiotensin
converting enzyme, ARBs = angiotensin receptor blockers, CCBs = calcium
channel blockers, N/A = nonapplicable.
primer sequences used and the laboratory conditions for
genotyping (polymerase chain reaction, restriction enzymes,
agarose electrophoresis) for each NOS3 polymorphism have
been previously described [12, 13]. Genotyping was per-
formed by laboratory personnel blinded to clinical status.
2.3. Statistical Analysis. All statistical analyses were per-
formed using the SAS software (v9.1 SAS Institute Inc,
NC, USA). The values for clinical parameters are expressed
as mean ± standard deviation. The Student t-test andInternational Journal of Hypertension 3
the chi-square test were used for comparisons of continu-
ous and categorical variables, respectively. Any result with
P < .05 was considered statistically signiﬁcant. The chi-
square test with one degree of freedom was used in order
to test whether the frequency distribution of genotypes
in the control group was in Hardy-Weinberg equilibrium
(HWE) (P ≥ .05). Diﬀerences in genotype distribution and
allele frequencies between hypertensive and control subjects
were tested using the chi-square test. The association was
expressed as an odds ratio (OR) with the corresponding
95% conﬁdence interval (95% CI). Multivariate logistic
regression analysis was also used to adjust for the eﬀects
of covariates (age, gender, BMI, and smoking status) on
the genotype-phenotype association. Addition of a squared
term of age was found to improve model ﬁt, as tested
with the likelihood ratio test, and was therefore kept in the
ﬁnal model. For the regression models, the genetic eﬀect
of the mutant allele (786C∗,4 a ∗, and 894T∗,r e s p . )w a s
assumed to be dominant (mutant carriers versus wild type
homozygotes),orrecessive(mutanthomozygotesversuswild
type carriers), or additive (mutant homozygotes versus wild
type homozygotes) or codominant (heterozygotes versus
homozygotes), for each NOS3 polymorphism [10]. Linkage
disequilibrium (LD) and haplotype analysis were performed
using the SHEsis and HAPSTAT software platforms [14,
15]. The order of variants in the inferred haplotypes was
T786C, 4a/b, G894T, corresponding to the physical location
of these variants in the NOS3 gene. The threshold haplotype
frequency value for inclusion in the analysis was set at
3%. Sample size calculations were performed by using the
Power Calculator for Genetic Studies [16] .Am o d e s tg e n e t i c
eﬀect (OR = 1.3), and observed disease prevalence (30%),
andminorallelefrequencies(786C∗ = 40%,4a∗ = 20%and
894T∗ = 35%) in Caucasian populations wereimputed [17].
Suﬃcient power (>80%) to detect modest genetic eﬀects
was achieved with a sample of 230 cases and 306 controls
for all three polymorphisms. A systematic review of the
literature for studies investigating the association between
NOS3 haplotypes and hypertension was also conducted and
the individual study results were summarized.
3. Results
The main clinical and demographic characteristics of the
subjects are summarized in Table 1.A g e ,m a l eg e n d e r ,
BMI, SBP, DBP, creatinine, and urea concentration were
signiﬁcantly higher in cases compared to controls. Among
cases, 28% suﬀered from coronary artery disease and almost
90% were treated by antihypertensive medications or statins.
Genotypingwassuccessfulin96%,99%,and99%ofsub-
jectsfortheT786C,4a/bandG894Tpolymorphisms,respec-
tively. The genotype distributions and allele frequencies are
shown in Table 2. The genotype distributions in the control
group were in HWE for all polymorphisms (P = .39, .63
and .16 for T786C, 4a/b, and G894T polymorphisms, resp.).
The genotype distribution diﬀered signiﬁcantly between
cases and controls only for the intronic 4a/b polymorphism
(Table 2). In univariate analysis under a dominant model,
Table 2: Genotypic and allelic distributions of NOS3 polymor-
phisms for cases and controls.
Cases, n (%) Controls, n (%) P-value
T786C
TT 69 (30.4) 101 (35.0)
TC 118 (52.0) 148 (51.2)
CC 40 (17.6) 40 (13.8) .37(a)
T alleles 246 (55.4) 350 (60.6)
C alleles 198 (44.6) 228 (39.4) .12(b)
Intron 4a/b
4b/b 165 (72.4) 190 (62.7)
4a/b 59 (25.9) 101 (33.3)
4a/a 4 (1.7) 12 (4.0) .04(a)
b alleles 389 (85.3) 481 (79.4)
a alleles 67 (14.7) 125 (20.6) .03(b)
G894T
GG 99 (43.4) 135 (44.7)
GT 95 (41.7) 130 (43.1)
TT 34 (14.9) 37 (12.2) .67(a)
G alleles 283 (63.5) 400 (66.2)
T alleles 163 (36.5) 204 (33.8) .39(b)
(a)P-value for the comparison of genotypic distribution. (b)P-value for the
comparison of the allelic distribution.
carriersofthemutantallelea∗ were36%lesslikelytodevelop
hypertension (OR = 0.64, 95% CI (0.44–0.93)) compared
to homozygotes of the wild type allele (b∗). However, this
protective eﬀect of the a∗ allele was no longer signiﬁcant
after adjustment for possible confounding variables using
multiple regression analysis (adjusted OR = 0.52, 95% CI
(0.26–1.04)) (Table 3). No signiﬁcant interaction between
thea∗ allelecarriershipandsmokingwasobserved(P = .44).
The remaining analyses, both univariate and multivariate,
did not show any signiﬁcant association for the T786C and
G894T polymorphisms and are shown in Table 3.
Pairwise LD among the three polymorphisms was
measured by the Lewontin standardized disequilibrium
coeﬃcient D  and the squared correlation coeﬃcient r2
[18], in both groups separately. All pairwise comparisons
showed statistically signiﬁcant LD (P<. 05), although strong
LD (D  > 0.8) was evident only for the 4a/b and G894T
polymorphisms in the control group (Table 4).
The distribution of the estimated haplotype frequencies
for cases and controls is presented in Table 5.S i xm a j o r
haplotypeswithfrequencies> 3%wereidentiﬁed.Theglobal
chi-square test for association of haplotypes showed that
there was an overall signiﬁcant diﬀerence between cases
and controls (P = .03). This diﬀerence was due to the
T-a-G∗ haplotype, which was more frequent in controls
(5.5%) compared to cases (2%) (P = .02), conferring a
protective eﬀect against the development of hypertension.
Exploration of possible interactions of the T-a-G∗ haplotype
with confounding variables (age, sex, BMI, smoking status)
did not detect any signiﬁcant results (P-values >. 05).4 International Journal of Hypertension
Table 3: Unadjusted and adjusted odds ratios with the corresponding 95% conﬁdence intervals for the association of NOS3 genotypes and
hypertension: comparisons for the dominant, recessive, additive, and codominant models of the mutant alleles (786C∗,4 a ∗, 894T∗).
Polymorphism Unadjusted P-value Adjusted P-value
OR (95% CI) OR (95% CI)
T786C
Dominant model 1.23 (0.85–1.79) .28 1.30 (0.64–2.63) .47
Recessive model 1.33 (0.83–2.15) .24 0.77 (0.33–1.83) .56
Additive model 1.46 (0.86–2.49) .16 0.99 (0.38–2.62) .98
Codominant model 1.03 (0.73–1.42) .86 1.48 (0.75–2.93) .26
Intron 4a/b
Dominant model 0.64 (0.44–0.93) .02 0.52 (0.26–1.04) .06
Recessive model 0.43 (0.14–1.36) .15 0.49 (0.08–3.07) .45
Additive model 0.38 (0.12–1.21) .10 0.40 (0.06–2.78) .35
Codominant model 0.69 (0.48–1.02) .06 0.56 (0.28–1.13) .10
G894T
Dominant model 1.05 (0.75–1.49) .77 1.51 (0.78–2.92) .22
Recessive model 1.25 (0.76–2.07) .37 1.04 (0.38–2.77) .94
Additive model 1.25 (0.74–2.14) .41 1.28 (0.46–3.56) .64
Codominant model 0.94 (0.67–1.34) .75 1.51 (0.77–2.96) .23
Table 4: Pairwise linkage disequilibrium metrics [D ,(r2)] for
NOS3 polymorphisms in cases and controls.
Polymorphisms Intron 4a/b G894T
T786C
Cases 0.46(a) (0.05)(a) 0.34(a) (0.09)(a)
Controls 0.44(a) (0.15)(a) 0.51(a) (0.11)(a)
Intron 4a/b
Cases — 0.44(a) (0.02)(a)
Controls — 0.82(a) (0.09)(a)
(a)P<. 05.
Table 5: NOS3 haplotype distribution in cases and controls.
Haplotype(a) Cases (%) Controls (%) P-value
T-b-G∗ 47.2 43.1 .26
C-b-T∗ 26.4 20.9 .07
C-a-G∗ 11.9 13.7 .43
T-b-T∗ 7.9 11.5 .09
C-b-G∗ 3.7 4.1 .77
T-a-G∗ 2 5.5 .02
other 0.9 1.2 —
Global test of association .03
(a)The order of variants in the inferred haplotypes is [T786C-4a/b-G894T]
in order to correspond to the physical location of these variants in the NOS3
gene.
Theliteraturesearchidentiﬁedninepreviouslypublished
studies on the association between NOS3 haplotypes and
hypertension [6, 7, 19–25] and their results are provided in
Table 6.
4. Discussion
4.1. Novel Findings. This study evaluated relations between
common genetic variants and haplotypes in the NOS3 gene
with essential hypertension. The single locus analysis among
the three most commonly studied polymorphisms revealed
an association only for the 4a/b polymorphism. Contrary to
what was anticipated, carriership of the mutant allele a∗ was
associated with a 36% reduction in the risk of developing
hypertension. A meta-analysis conducted by our group has
previously shown a detrimental eﬀect for the a∗ allele; based
on unadjusted estimates, the a∗ allele was associated with
an 22% increased risk for hypertension [5]. Interestingly,
this association was conﬁned in Caucasians. In the current
study, the unadjusted analysis in a Caucasian population
revealed an association in the opposite direction (protective
eﬀect of the a∗ allele). However, this association was not
signiﬁcant when the eﬀects of potential confounders were
taken into account with a multivariate logistic regression
model. Additionally, previous reports have described that
the 4a/b polymorphism eﬀects can be smoking-dependent
[26, 27]. No signiﬁcant genotype-smoking interactions were
found in our analysis. The lack of association for the G894T
and T786C polymorphisms was in concordance with the
meta-analysis results [5].
In the haplotype-based association analysis, the distri-
bution of a relatively infrequent haplotype (T-a-G∗)w a s
found to be diﬀerent between cases and controls, resulting
in a protective eﬀect against hypertension. The mutant
allele of the 4a/b polymorphism is incorporated in this
haplotype, along with the two wild type alleles of G894T
and T786C polymorphisms. Although not signiﬁcant in
individual analyses, the point estimates of the genetic eﬀects
of the alleles involved in this haplotype were also in the
protective direction (Table 3). This study could not provideInternational Journal of Hypertension 5
Table 6: Summary description of previous studies on the association between NOS3 haplotypes and essential hypertension.
Study ﬁrst
author, year of
publication
Study population
ethnicity, (Number
of cases/Number of
controls)
Evidence for
association with
NOS3 haplotypes
Haplotypes with
statistically
signiﬁcant results
Direction of
haplotypic genetic
eﬀect
Sandrim, 2006 Caucasians
Yes
T-b-T∗ Protective
[21] (112/113) C-b-G∗ Protective
C-b-T∗ Susceptibility
Blacks (91/87) Yes T-b-T∗ Protective
C-b-G∗ Protective
Sandrim, 2006 Mixed Yes C-b-G∗ Protective
[22] (119/102) C-b-T∗ Susceptibility
Zhao, 2006 East-Asians No
[23] (503/490)
Sandrim, 2006 Mixed Yes C-b-G∗ Protective
[24] (216/111) C-b-T∗ Susceptibility
Sandrim, 2007 Mixed Yes C-b-G∗ Protective
[7] (154/98) C-b-T∗ Susceptibility
Nejatizadeh,
2008 [6]
Indian (455/345) Yes
T-a-G∗ Protective
T-a-T∗ Protective
C-a-G∗ Protective
T-b-G∗ Susceptibility
Conen, 2008
[25] Caucasian (18436) No
Kumar, 2009
[19]
Indian (440/470) Yes
T-a-G∗ Susceptibility
T-a-T∗ Susceptibility
C-a-G∗ Susceptibility
T-b-G∗ Protective
Vasconcellos,
2010 [20] Caucasians Yes C-b-G∗ Protective
(173/101) C-a-G∗ Susceptibility
any further information regarding the underlying culprit
functional variation captured by this haplotype; however,
the LD analysis showed evidence of strong LD between the
4a/bandtheG894Tpolymorphismsincontrols,whichcould
potentially pinpoint a locus of interest.
4.2. Haplotype Testing in Hypertension. Testing of haplotypes
overcomes some of the problems encountered with using
single polymorphisms in genetic association studies, because
the interaction of multiple genetic markers within a hap-
lotype could be a key determinant of disease susceptibility
rather than the individual polymorphism [28, 29]. The
haplotype analysis approach is expected to be more pow-
erful than single-marker analysis, because of the ancestral
structure incarcerated in the distribution of haplotypes
[9, 10]. Particularly if the markers used deﬁne mutations
within functional DNA then the haplotypes composed
of these markers can have more of a biological role. In
accordance with this hypothesis, no signiﬁcant associations
were detected for the single-marker analysis promoter
(T786C) and the nonsynonymous (G894T) variants used in
our study, despite the fact that functionality analyses have
demonstrated a role for both variants [3].
Previous studies have yielded contradictory results
regarding the role of the T-a-G∗ haplotype that was found
to be protective in our study, as shown in Table 6. Although
no correlation with NO production has been detected [7],
the T-a-G∗ has been reported to confer susceptibility to
hypertension [19]o rt ob ep r o t e c t i v ea g a i n s tg e s t a t i o n a l
hypertension and preeclampsia [30]. Since the haplotypic
structure has not been previously examined in the Greek
population, it is possible that ethnicity may account for the
observed discrepancies. The T-a-G∗ haplotype had a lower
frequency in our study (2% and 5.5% in cases and controls)
compared to previous reports (ranging from 6% to 20%)
[19, 30].
For complex disorders as hypertension, the rare hap-
lotypes have been recently shown to play a signiﬁcant6 International Journal of Hypertension
role in inﬂuencing disease susceptibility [31, 32]. Recent
paradigms have also shown that hunting common variation
will not probably suﬃce to track the “missing heritabil-
ity” explained by variants detected in the genome-wide
association era [33, 34]. Multiple rare pathogenic variants
are also likely to be important determinants of complex
disorders. Although such variants will not be detectable by
current techniques based on the use of linked polymorphic
markers, advances in genotyping technologies and novel
genetic variation maps that capture rare variants (1,000
Genomes Project) will make whole-genome searches for rare
variants feasible [35]. Findings from genome-wide agnostic
approaches can nevertheless be complemented by prioritized
results from additional venues of genomic research (genomic
convergence) [36, 37] in order to select for replication
studies the candidate genes with the stronger evidence
support.
4.3. Study Limitations. Large sample sizes and independent
replication are sine qua non principles for genetic epidemi-
ology [10, 38]. Our ﬁndings are not supportive of a major
contributory role of individual genetic polymorphisms but
provide evidence for association for a rare haplotype. Given
the logistic limitations of single centers, like ours, to recruit
large numbers of participants and to replicate the association
in multiple cohorts, it is important that the validity of
the proposed association here is tested in other studies
before scrutinizing the gene in search for causal variants.
Additionally, complex disorders such as hypertension are
considered to emerge from multiple epistatic and gene-
environmental interactions [34]. Although the NOS3 gene is
though to be involved in critical pathway interplays [39], our
sample size did not allow the testing for interactions with
suﬃcient power. Finally, the case-control design may have
allowed for some elusive misclassiﬁcation of controls, since
the development of the disease is age-related. Replicating our
hypothesis in large prospective studies could overcome these
unavoidable limitations [38].
In conclusion, our genetic association study detected a
protective eﬀect of a rare NOS3 haplotype against hyperten-
sion. Although the underlying functional genetic variation
in the NOS3 gene remains to be deﬁned, haplotype-based
analyses are expected to be more informative regarding the
role of the NOS3 gene compared to single-marker analyses.
Rare haplotypes and variants may not serve as markers of
disease with clinical utility on a population-wide basis but
they hold the potential to uncover critical pathways involved
in the pathogenesis of hypertension and assist in deﬁning
novel molecular targets for intervention. Our results require
replication in independent cohorts and additional studies
in order to disentangle the molecular basis of the detected
genetic eﬀects.
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